{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T05:42:47Z","timestamp":1781934167466,"version":"3.54.5"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,3,26]],"date-time":"2023-03-26T00:00:00Z","timestamp":1679788800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005040","name":"Bontius Stichting","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005040","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005039","name":"Leids Universitair Medisch Centrum","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005039","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bone"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.bone.2023.116744","type":"journal-article","created":{"date-parts":[[2023,3,21]],"date-time":"2023-03-21T15:41:14Z","timestamp":1679413274000},"page":"116744","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Clinical value of RANKL, OPG, IL-6 and sclerostin as biomarkers for fibrous dysplasia\/McCune-Albright syndrome"],"prefix":"10.1016","volume":"171","author":[{"given":"M.E.","family":"Meier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Hagelstein-Rotman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.C.M.","family":"Streefland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.M.","family":"Winter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Bravenboer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.M.","family":"Appelman-Dijkstra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"24","key":"10.1016\/j.bone.2023.116744_bb0005","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1056\/NEJM199112123252403","article-title":"Activating mutations of the stimulatory G protein in the McCune\u2013Albright syndrome","volume":"325","author":"Weinstein","year":"1991","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.bone.2023.116744_bb0010","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1210\/endrev\/bnz011","article-title":"Fibrous Dysplasia\/McCune-albright syndrome: a rare, mosaic disease of G\u03b1 s activation","volume":"41","author":"Boyce","year":"2019","journal-title":"Endocr. Rev."},{"issue":"6","key":"10.1016\/j.bone.2023.116744_bb0015","first-page":"1587","article-title":"Fibrous dysplasia of bone in the McCune-albright syndrome: abnormalities in bone formation","volume":"151","author":"Riminucci","year":"1997","journal-title":"Am. J. Pathol."},{"issue":"1","key":"10.1016\/j.bone.2023.116744_bb0020","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1186\/s13023-019-1102-9","article-title":"Best practice management guidelines for fibrous dysplasia\/McCune-albright syndrome: a consensus statement from the FD\/MAS international consortium","volume":"14","author":"Javaid","year":"2019","journal-title":"Orphanet J. Rare Dis."},{"issue":"2","key":"10.1016\/j.bone.2023.116744_bb0025","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1359\/JBMR.041111","article-title":"An instrument to measure skeletal burden and predict functional outcome in fibrous dysplasia of bone","volume":"20","author":"Collins","year":"2005","journal-title":"J. Bone Miner. Res."},{"issue":"8","key":"10.1016\/j.bone.2023.116744_bb0030","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1002\/jbmr.4618","article-title":"Skeletal disease Acquisition in Fibrous Dysplasia: natural history and indicators of lesion progression in children","volume":"37","author":"Szymczuk","year":"2022","journal-title":"J. Bone Miner. Res."},{"issue":"5","key":"10.1016\/j.bone.2023.116744_bb0035","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1016\/j.cell.2018.03.018","article-title":"Disease-causing mutations in the G protein G\u03b1s subvert the roles of GDP and GTP","volume":"173","author":"Hu","year":"2018","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.bone.2023.116744_bb0040","first-page":"981","article-title":"Cellular and molecular basis of fibrous dysplasia","volume":"16","author":"Marie","year":"2001","journal-title":"Histol. Histopathol."},{"issue":"5","key":"10.1016\/j.bone.2023.116744_bb0045","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1359\/jbmr.091036","article-title":"Transfer, analysis, and reversion of the fibrous dysplasia cellular phenotype in human skeletal progenitors","volume":"25","author":"Piersanti","year":"2010","journal-title":"J. Bone Miner. Res."},{"issue":"1","key":"10.1016\/j.bone.2023.116744_bb0050","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1172\/JCI118773","article-title":"Increased IL-6-production by cells isolated from the fibrous bone dysplasia tissues in patients with McCune-albright syndrome","volume":"98","author":"Yamamoto","year":"1996","journal-title":"J. Clin. Invest."},{"issue":"3","key":"10.1016\/j.bone.2023.116744_bb0055","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/S8756-3282(03)00064-4","article-title":"Osteoclastogenesis in fibrous dysplasia of bone: in situ and in vitro analysis of IL-6 expression","volume":"33","author":"Riminucci","year":"2003","journal-title":"Bone"},{"issue":"4","key":"10.1016\/j.bone.2023.116744_bb0060","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1002\/jbmr.3649","article-title":"Age-related changes and effects of bisphosphonates on bone turnover and disease progression in fibrous dysplasia of bone","volume":"34","author":"Florenzano","year":"2019","journal-title":"J. Bone Miner. Res."},{"issue":"6","key":"10.1016\/j.bone.2023.116744_bb0065","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1007\/s00259-019-04657-1","article-title":"Quantifying skeletal burden in fibrous dysplasia using sodium fluoride PET\/CT","volume":"47","author":"van der Bruggen","year":"2020","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"2","key":"10.1016\/j.bone.2023.116744_bb0070","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1002\/jbmr.2999","article-title":"Outcome of long-term bisphosphonate therapy in McCune-albright syndrome and polyostotic fibrous dysplasia","volume":"32","author":"Majoor","year":"2017","journal-title":"J. Bone Miner. Res."},{"issue":"2","key":"10.1016\/j.bone.2023.116744_bb0075","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1002\/jbmr.3602","article-title":"Activation of RANK\/RANKL\/OPG pathway is involved in the pathophysiology of fibrous dysplasia and associated with disease burden","volume":"34","author":"De Castro","year":"2019","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2023.116744_bb0080","first-page":"1","article-title":"Sclerostin, an emerging therapeutic target for treating osteoporosis and osteoporotic fracture: a general review","volume":"4","author":"Suen","year":"2016","journal-title":"J. Orthop. Transl."},{"key":"10.1016\/j.bone.2023.116744_bb0085","article-title":"Nanostring technology on fibrous dysplasia bone biopsies. A pilot study suggesting different histology-related molecular profiles","volume":"16","author":"Persichetti","year":"2022","journal-title":"Bone Rep."},{"issue":"1","key":"10.1016\/j.bone.2023.116744_bb0090","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0227279","article-title":"Changes in gene expression in human skeletal stem cells transduced with constitutively active Gs\u03b1 correlates with hallmark histopathological changes seen in fibrous dysplastic bone","volume":"15","author":"Raimondo","year":"2020","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.bone.2023.116744_bb0095","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0094989","article-title":"Disrupted bone remodeling leads to Cochlear overgrowth and hearing loss in a mouse model of fibrous dysplasia","volume":"9","author":"Akil","year":"2014","journal-title":"PLOS ONE"},{"key":"10.1016\/j.bone.2023.116744_bb0100","series-title":"Clinical Metabolomics: Methods and Protocols","first-page":"361","article-title":"Quality-assured biobanking: the leiden university medical center model","author":"Haumann","year":"2018"},{"issue":"12","key":"10.1016\/j.bone.2023.116744_bb0105","doi-asserted-by":"crossref","first-page":"6069","DOI":"10.1210\/jc.2018-02543","article-title":"Denosumab in patients with fibrous dysplasia previously treated with bisphosphonates","volume":"104","author":"Majoor","year":"2019","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"9","key":"10.1016\/j.bone.2023.116744_bb0110","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1002\/jbmr.4380","article-title":"Safety of therapy with and withdrawal from denosumab in fibrous dysplasia and McCune-Albright syndrome: an observational study","volume":"36","author":"Meier","year":"2021","journal-title":"J. Bone Miner. Res."},{"issue":"1","key":"10.1016\/j.bone.2023.116744_bb0115","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1186\/s13023-022-02588-z","article-title":"A multidisciplinary care pathway improves quality of life and pain in patients with fibrous dysplasia\/McCune-Albright syndrome: a multicenter prospective observational study","volume":"17","author":"Meier","year":"2022","journal-title":"Orphanet J. Rare Dis."},{"issue":"2","key":"10.1016\/j.bone.2023.116744_bb0120","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1002\/jbmr.4463","article-title":"Long bone fractures in fibrous Dysplasia\/McCune-albright syndrome: prevalence, natural history, and risk factors","volume":"37","author":"Geels","year":"2022","journal-title":"J. Bone Miner. Res."},{"issue":"2","key":"10.1016\/j.bone.2023.116744_bb0125","first-page":"129","article-title":"Pain assessment: global use of the brief pain inventory","volume":"23","author":"Cleeland","year":"1994","journal-title":"Ann. Acad. Med. Singap."},{"issue":"6","key":"10.1016\/j.bone.2023.116744_bb0130","doi-asserted-by":"crossref","first-page":"e2258","DOI":"10.1210\/clinem\/dgac120","article-title":"Neuropathic-like pain in fibrous Dysplasia\/McCune-albright syndrome","volume":"107","author":"Spencer","year":"2022","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"1","key":"10.1016\/j.bone.2023.116744_bb0135","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1186\/1750-1172-7-S1-S3","article-title":"Pathophysiology and medical treatment of pain in fibrous dysplasia of bone","volume":"7","author":"Chapurlat","year":"2012","journal-title":"Orphanet J. Rare Dis."},{"issue":"1","key":"10.1016\/j.bone.2023.116744_bb0140","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1186\/s12974-016-0607-6","article-title":"Interleukin-6: an emerging regulator of pathological pain","volume":"13","author":"Zhou","year":"2016","journal-title":"J. Neuroinflammation"},{"issue":"10","key":"10.1016\/j.bone.2023.116744_bb0145","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1359\/jbmr.1997.12.10.1746","article-title":"Long-term effects of intravenous pamidronate in fibrous dysplasia of bone","volume":"12","author":"Chapurlat","year":"1997","journal-title":"J. Bone Miner. Res."},{"issue":"1","key":"10.1016\/j.bone.2023.116744_bb0150","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.bone.2004.03.004","article-title":"Treatment of fibrous dysplasia of bone with intravenous pamidronate: long-term effectiveness and evaluation of predictors of response to treatment","volume":"35","author":"Chapurlat","year":"2004","journal-title":"Bone"},{"key":"10.1016\/j.bone.2023.116744_bb0155","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1097\/00003086-200101000-00003","article-title":"Bisphosphonate therapy in fibrous dysplasia","volume":"382","author":"Lane","year":"2001","journal-title":"Clin. Orthop. Relat. Res."},{"issue":"11","key":"10.1016\/j.bone.2023.116744_bb0160","doi-asserted-by":"crossref","first-page":"4133","DOI":"10.1210\/jc.2014-1371","article-title":"A randomized, double blind, placebo-controlled trial of alendronate treatment for fibrous dysplasia of bone","volume":"99","author":"Boyce","year":"2014","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"1","key":"10.1016\/j.bone.2023.116744_bb0165","doi-asserted-by":"crossref","first-page":"23","DOI":"10.4158\/EP-2018-0328","article-title":"Efficacy and safety of bisphosphonate therapy in McCune-albright syndrome-related polyostotic fibrous dysplasia: a single-center experience","volume":"25","author":"Wang","year":"2019","journal-title":"Endocr. Pract."},{"key":"10.1016\/j.bone.2023.116744_bb0170","series-title":"Anti-RANKL Treatment in a Murine Model of Fibrous Dysplasia","author":"Palmisano","year":"2017"},{"issue":"12","key":"10.1016\/j.bone.2023.116744_bb0175","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1002\/jbmr.3828","article-title":"RANKL inhibition in fibrous dysplasia of bone: a preclinical study in a mouse model of the human disease","volume":"34","author":"Palmisano","year":"2019","journal-title":"J. Bone Miner. Res."},{"issue":"8","key":"10.1016\/j.bone.2023.116744_bb0180","doi-asserted-by":"crossref","first-page":"e2980","DOI":"10.1210\/clinem\/dgab212","article-title":"Denosumab reduces lesional fluoride skeletal burden on Na[18F]F PET-CT in patients with fibrous Dysplasia\/McCune-albright syndrome","volume":"106","author":"Van der Bruggen","year":"2021","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"7","key":"10.1016\/j.bone.2023.116744_bb0185","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1359\/jbmr.1999.14.7.1104","article-title":"Glucocorticoids decrease interleukin-6 levels and induce mineralization of cultured osteogenic cells from children with fibrous dysplasia","volume":"14","author":"Stanton","year":"1999","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2023.116744_bb0190","doi-asserted-by":"crossref","DOI":"10.1016\/j.bone.2022.116343","article-title":"Inhibition of IL-6 in the treatment of fibrous dysplasia of bone: the randomized double-blind placebo-controlled TOCIDYS trial","volume":"157","author":"Chapurlat","year":"2022","journal-title":"Bone"}],"container-title":["Bone"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328223000777?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328223000777?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T18:04:15Z","timestamp":1757613855000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S8756328223000777"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":38,"alternative-id":["S8756328223000777"],"URL":"https:\/\/doi.org\/10.1016\/j.bone.2023.116744","relation":{},"ISSN":["8756-3282"],"issn-type":[{"value":"8756-3282","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical value of RANKL, OPG, IL-6 and sclerostin as biomarkers for fibrous dysplasia\/McCune-Albright syndrome","name":"articletitle","label":"Article Title"},{"value":"Bone","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bone.2023.116744","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"116744"}}